What You Should Know:
– Strados Labs, a medical technology company focused on respiratory health, today announced a new collaboration with Beth Israel Deaconess Medical Center (BIDMC) to evaluate the use of its RESP® Biosensor for the early detection of pulmonary edema in critically ill patients.
– The pilot study, scheduled to begin at the end of February 2025, will enroll 20 patients and is expected to last 12 months.
Study Design and Objectives
Pulmonary edema, a condition where fluid accumulates in the lungs, is a common and life-threatening complication for patients on mechanical ventilation (MV). Early detection is crucial for effective intervention and improved outcomes. This study will investigate whether the RESP Biosensor, a wearable stethoscope technology, can detect subtle changes in lung sounds that precede traditional markers of pulmonary edema.
This single-center, prospective, observational study will compare the performance of the RESP Biosensor to existing monitoring methods, such as daily chest X-rays, clinical assessments, and fluid intake/output tracking. The primary objective is to determine if the biosensor can identify early signs of pulmonary edema before they are detectable through conventional methods.
RESP Biosensor: A Breakthrough in Continuous Lung Monitoring
The RESP Biosensor is an FDA-cleared and CE-marked wearable device that continuously captures lung sounds, including cough, wheeze, and crackles. This technology has been used in various patient populations and disease states, such as chronic cough, COPD, asthma, and heart failure. This study marks the first time the RESP Biosensor will be used to monitor patients on MV for pulmonary edema.
Expanding Applications for Lung Sound Monitoring
This study is part of a broader effort to evaluate the potential of the RESP Biosensor to improve patient care across various respiratory conditions. The findings are expected to guide future research and expand the applications of continuous lung sound monitoring.
“Pulmonary edema presents significant challenges in the ICU, with delayed detection often leading to poorer outcomes for patients,” said Nick Delmonico, CEO & Cofounder at Strados Labs. “We’re excited to collaborate with the esteemed team at BIDMC to explore whether continuous monitoring of lung sounds could lead to earlier and prompt interventions in pulmonary edema.”
